二甲双胍对单纯性肥胖患者血清MCP-1水平及体成分的影响

Effect of metformin on serum mcp-1 and body composition in simple obese patients

目的:探讨二甲双胍对单纯性肥胖患者空腹血清单核细胞趋化蛋-白1(monocyte chemoattractantprotein-1,MCP-1)水平与体成分的影响及与体成分的相关性。方法:采用酶联免疫法和生物电阻抗仪分别测定单纯性肥胖患者、健康对照者以及经二甲双胍治疗12周后的肥胖患者的空腹血清MCP-1水平和体成分,对MCP-1水平和体成分进行分组比较,并分析与体成分相关性。结果:单纯性肥胖患者血清MCP-1水平明显高于健康对照者(P<0.05);肥胖患者经二甲双胍治疗后血清MCP-1水平显著降低(P<0.05);相关分析显示:血清MCP-1水平与体重指数(body mass index,BMI)(r=0.326,P<0.05)、腰围(r=0.344,P<0.05)呈正相关。结论:单纯性肥胖患者MCP-1水平较正常人高,二甲双胍治疗可以降低血清MCP-1水平,从而改善致动脉粥样硬化的炎性反应。

Objective： To investigate the effect of mefformin on serum level of monocyte chemoattractant protein-1 （ MCP-1 ） and body compositon in obese patients and the correlation between MCP-1 and body composition. Methods： Fasting serum level of MCP-1 was assayed by ELISA in controls, obese patients, and patients accepted 12- week treatment with metfonnin. Body composition was detected by bioelectrical impedance analysis in all objects. The differences of MCP-1 and body composition among different groups and the relations between serum level of MCP-1 and body composition were also analyzed. Results： Serum level of MCP-1 in obese patients was significantly increased compared with controls（ P 〈 0.05）, while serum level of MCP-1 in patients treated with mefformin for 12 weeks was significantly decreased（ P 〈 0.05）. Serum MCP-1 levels positively correlated with body mass index（BMI） （ r = 0.326, P 〈 0.05） and waist circumference（ r = 0.344, P 〈 0.05）. Conclusion： Obese patients exhibit a increased serum level of MCP-1. Meffonnin can decrease the circulating MCP-1 level and improve the inflammatory processes involved in atherogenesis.